381 related articles for article (PubMed ID: 19557013)
1. Therapeutic strategies within the ubiquitin proteasome system.
Eldridge AG; O'Brien T
Cell Death Differ; 2010 Jan; 17(1):4-13. PubMed ID: 19557013
[TBL] [Abstract][Full Text] [Related]
2. Targeting the ubiquitin proteasome system in haematological malignancies.
Crawford LJ; Irvine AE
Blood Rev; 2013 Nov; 27(6):297-304. PubMed ID: 24183816
[TBL] [Abstract][Full Text] [Related]
3. Drug discovery in the ubiquitin-proteasome system.
Nalepa G; Rolfe M; Harper JW
Nat Rev Drug Discov; 2006 Jul; 5(7):596-613. PubMed ID: 16816840
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the identification of ubiquitin ligase inhibitors.
Goldenberg SJ; Marblestone JG; Mattern MR; Nicholson B
Biochem Soc Trans; 2010 Feb; 38(Pt 1):132-6. PubMed ID: 20074047
[TBL] [Abstract][Full Text] [Related]
5. Targeting the ubiquitin+proteasome system in solid tumors.
Driscoll JJ; Woodle ES
Semin Hematol; 2012 Jul; 49(3):277-83. PubMed ID: 22726552
[TBL] [Abstract][Full Text] [Related]
6. A patent review of the ubiquitin ligase system: 2015-2018.
Li X; Elmira E; Rohondia S; Wang J; Liu J; Dou QP
Expert Opin Ther Pat; 2018 Dec; 28(12):919-937. PubMed ID: 30449221
[TBL] [Abstract][Full Text] [Related]
7. The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.
Yerlikaya A; Kanbur E; Stanley BA; Tümer E
Anticancer Agents Med Chem; 2021; 21(1):20-32. PubMed ID: 32781973
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ubiquitin proteasome system: beyond proteasome inhibition.
Xolalpa W; Perez-Galan P; Rodríguez MS; Roué G
Curr Pharm Des; 2013; 19(22):4053-93. PubMed ID: 23181575
[TBL] [Abstract][Full Text] [Related]
9. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
Guharoy M; Bhowmick P; Tompa P
J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
[TBL] [Abstract][Full Text] [Related]
10. The ubiquitin-proteasome system.
Nandi D; Tahiliani P; Kumar A; Chandu D
J Biosci; 2006 Mar; 31(1):137-55. PubMed ID: 16595883
[TBL] [Abstract][Full Text] [Related]
11. The Small Molecules Targeting Ubiquitin-Proteasome System for Cancer Therapy.
Ao N; Chen Q; Liu G
Comb Chem High Throughput Screen; 2017; 20(5):403-413. PubMed ID: 28699494
[TBL] [Abstract][Full Text] [Related]
12. Ubiquitination and deubiquitination: Implications on cancer therapy.
Dagar G; Kumar R; Yadav KK; Singh M; Pandita TK
Biochim Biophys Acta Gene Regul Mech; 2023 Dec; 1866(4):194979. PubMed ID: 37633647
[TBL] [Abstract][Full Text] [Related]
13. Proteasome substrate receptors and their therapeutic potential.
Osei-Amponsa V; Walters KJ
Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
[TBL] [Abstract][Full Text] [Related]
14. Role of the ubiquitin proteasome system in hematologic malignancies.
Sahasrabuddhe AA; Elenitoba-Johnson KS
Immunol Rev; 2015 Jan; 263(1):224-39. PubMed ID: 25510280
[TBL] [Abstract][Full Text] [Related]
15. Targeting the ubiquitin-proteasome system to activate wild-type p53 for cancer therapy.
Allende-Vega N; Saville MK
Semin Cancer Biol; 2010 Feb; 20(1):29-39. PubMed ID: 19897040
[TBL] [Abstract][Full Text] [Related]
16. [Ubiquitin-proteasome pathway as a target for therapeutic strategies].
Staszczak M
Postepy Biochem; 2017; 63(4):287-303. PubMed ID: 29374430
[TBL] [Abstract][Full Text] [Related]
17. A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome.
Liu J; Zheng H; Tang M; Ryu YC; Wang X
Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2541-50. PubMed ID: 18978187
[TBL] [Abstract][Full Text] [Related]
18. Targeting the ubiquitin pathway for cancer treatment.
Liu J; Shaik S; Dai X; Wu Q; Zhou X; Wang Z; Wei W
Biochim Biophys Acta; 2015 Jan; 1855(1):50-60. PubMed ID: 25481052
[TBL] [Abstract][Full Text] [Related]
19. Recent Patents on Proteasome Inhibitors of Natural Origin.
da Silva DC; Andrade PB; Ribeiro V; Valentao P; Pereira DM
Recent Pat Anticancer Drug Discov; 2017; 12(1):4-15. PubMed ID: 27881056
[TBL] [Abstract][Full Text] [Related]
20. Screening for E3-ubiquitin ligase inhibitors: challenges and opportunities.
Landré V; Rotblat B; Melino S; Bernassola F; Melino G
Oncotarget; 2014 Sep; 5(18):7988-8013. PubMed ID: 25237759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
